Biomarker Core

生物标志物核心

• 批准号: 10413099
• 负责人: ADAM M BRICKMAN
• 金额: $ 35.44万
• 依托单位: COLUMBIA UNIVERSITY HEALTH SCIENCES
• 依托单位国家: 美国
• 财政年份: 2020
• 资助国家: 美国
• 起止时间: 2020-06-15 至 2025-04-30
• 项目状态: 未结题
• 来源: https://reporter.nih.gov/project-details/10413099
• 关键词: APLP1 gene; Alzheimer' s Disease; Alzheimer’s disease biomarker; Amyloid; Apolipoproteins; Biological; Biological Markers; Blood; Cerebrospinal Fluid; Cerebrovascular Disorders; Cholesterol Homeostasis; Classification Scheme; Clinical; Cognitive aging; Communities; Data; Data Sources; Data Store; Databases; Dementia; Detection; Development; Diagnostic; Disease; Enrollment; Etiology; Goals; Heterogeneity; Human; Immune response; Immunologic Markers; Infarction; Information Systems; Infrastructure; International; Light; Liquid substance; MRI Scans; Magnetic Resonance Imaging; Measurement; Methods; Molecular; Nerve Degeneration; Participant; Pathway interactions; Plasma; Positron-Emission Tomography; Process; Protocols documentation; Radiology Specialty; Research; Research Personnel; Research Proposals; Resources; Scanning; Scientist; Secure; Sensitivity and Specificity; Standardization; Stream; Technology; Thick; Universities; White Matter Hyperintensity; Work; base; brain magnetic resonance imaging; cerebrovascular; data exchange; exosome; imaging biomarker; improved; in vivo; instrumentation; interest; magnetic resonance imaging biomarker; neurofilament; neuroimaging; neuroimaging marker; next generation; novel; novel marker; potential biomarker; programs; single molecule; sulfated glycoprotein 2; tau Proteins; trafficking; training opportunity

BIOMARKER CORE PROJECT SUMMARY/ABSTRACT The ability to study Alzheimer’s disease (AD) and related disorders has been revolutionized by the development and application of in vivo biomarkers. Analysis of cerebrospinal fluid (CSF), positron emission tomography (PET), and magnetic resonance imaging (MRI) allow operational measurement of amyloid, tau, and neurodegeneration (A/T/N), the major pathophysiological changes that define AD. Moreover, improved sensitivity and specificity of instrumentation applied to biofluid data, of neuroimaging protocols, and of analytic approaches both enable and necessitate the development, refinement, and discovery of novel biomarkers in any comprehensive AD research program. The Columbia University ADRC Biomarker Core embraces these theme and will derive standard biofluid and MRI biomarkers for all ADRC participants; serve as a central hub for human biofluid, PET, and MRI-based biomarker research conducted within the cognitive aging and dementia community at Columbia University; develop and implement novel biomarkers; and provide training opportunities for investigators interested in incorporating AD-related biomarkers into their research. The Biomarker Core leverages unique data sources, infrastructural, and intellectual strengths already in place and comprises a team of close-collaborating investigators instrumental to the majority of ongoing AD biomarker studies at Columbia University. The Biomarker Core will analyze research grade MRI scans acquired from harmonized clinical scans, from ongoing studies, or de novo for neurodegenerative and cerebrovascular markers. The Core features a newly-acquired single molecule array (Simoa) Benchtop Multiplexed Biomarker Detection Analyzer and Mesoscale Discovery (MSD) platform for analysis of CSF and blood and development of novel biomarkers. These resources will be used to derive existing blood- and CSF-based biomarkers and to develop novel ones. The deep biomarker characterization of all ADRC participants and close interaction with the other Cores will increase understanding of disease etiology and heterogeneity. The Biomarker Core has the following aims: 1) To harmonize, bank, and disseminate fluid and neuroimaging biomarker data derived from participants enrolled by the Clinical Core; 2) To quantitate biofluid biomarkers and MRI markers of neurodegeneration and cerebrovascular disease, according to the A/T/N classification scheme; 3) To develop, optimize, and implement biomarkers of the three thematic biological pathways: immune response, cholesterol metabolism, and endosomal trafficking; 4) To provide intellectual, analytic, and infrastructural support to local investigators interested in incorporating blood-based, CSF, MRI, and PET imaging biomarkers into their Alzheimer’s-related research programs; and 5) To provide training and training opportunities for the next generation of diverse scientists interested in incorporating biomarkers into the study of cognitive aging and dementia.

生物标志物核心项目摘要/摘要 研究阿尔茨海默氏病（AD）和相关疾病的能力已因发展而彻底改变 和体内生物标志物的应用。脑脊液（CSF），正电子发射断层扫描的分析 （PET）和磁共振成像（MRI）允许淀粉样蛋白，TAU和 神经变性（A/T/N），定义AD的主要病理生理变化。而且，改进 适用于生物流体数据，神经影像方案和分析的仪器的敏感性和特异性 启用和必要 全面的广告研究计划。哥伦比亚大学ADRC生物标志物核心拥抱这些主题 并将为所有ADRC参与者提供标准的生物流体和MRI生物标志物；充当人类的中心枢纽 生物流体，宠物和基于MRI的生物标志物研究在认知衰老和痴呆症社区内进行 在哥伦比亚大学；开发和实施新颖的生物标志物；并为培训机会 有兴趣将与广告相关的生物标志物导入其研究的研究者。 生物标志物核心利用独特的数据源，基础架构和智力优势已经存在 并组成了一支群落的调查员团队，对大多数正在进行的广告生物标志物有帮助 哥伦比亚大学的研究。生物标志物核心将分析从中获得的研究等级MRI扫描 从正在进行的研究或神经退行性和脑血管的从头研究或从头开始的临床扫描 标记。核心具有新获得的单分子阵列（SIMOA）台式多路复用生物标志物 检测分析仪和中尺度发现（MSD）平台，用于分析CSF以及血液与发展 新型生物标志物。这些资源将用于得出现有的基于血液和CSF的生物标志物，并将其用于 发展新颖的。所有ADRC参与者的深层生物标志物表征以及与 其他核心将增加对疾病病因和异质性的理解。生物标志物核有 以下目的：1）协调，库存和传播流体和神经影像学的生物标志物数据 参与者由临床核心入学； 2）定量生物流体生物标志物和MRI标记 根据A/T/N分类方案，神经变性和脑血管疾病； 3）发展， 优化和实施三种主题生物学途径的生物标志物：免疫反应，胆固醇 代谢和内体贩运； 4）向本地提供近视，分析和基础架构支持 有兴趣将基于血液，CSF，MRI和PET成像生物标志物纳入其的研究者 阿尔茨海默氏症与研究计划； 5）为下一个提供培训机会 有兴趣将生物标志物纳入认知衰老和 失智。